EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Transgene SA (0OCQ) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Transgene SA €1.62, price €0.70, upside +131.4%, quality 20 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Energy · GB · Home France · ISIN FR0005175080

TS Thin data Sep 24, 2026

Transgene SA

0OCQ · LSE

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value €1.62 · Strongly undervalued (+131.4%)
!Quality 20/100
!Weak Growth (revenue 5y −46.0 %/yr)
!Low debt · negative free cash flow
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch Transgene SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€2.81 €0.5800 Fair Value €1.62 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range €0.5800 – €2.81 · fair‑value band €1.07 – €2.02 · the €0.7000 price screens below the €1.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.

Show more

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, and BioInvent. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Stock analysis

Transgene SA (0OCQ) currently trades at €0.7000, while our model-based Fair Value estimate is €1.62, implying the stock looks roughly 56.8% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: €1.07 (bear) to €2.02 (bull), the price of €0.7000 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Energy sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Transgene SA reported revenue of €137K in FY2025 versus €10.0M in FY2021, a compound −65.8%/yr. Reported net income was −€37.5M in FY2025.

Key figures

Market cap €47.1M · P/S ratio 6.53 · EPS (TTM) €−0.2140 · Return on equity −54.8% · Return on assets (EBIT) −56.2% · Operating margin −684% · Revenue growth (YoY) −12.2% · Free cash flow −€37.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Energy peers we cover trades at −20% fair-value upside, at 131%, 0OCQ screens cheaper than that median.

Fair Value models

Bear €1.07 Fair Value €1.62 Bull €2.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) €0.9800 €1.31 €1.95 54
All 1 models by family
Asset-Based
NCAV (Graham) €0.9800 €1.31 €1.95 54

Open the full fair value analysis →

Notify me when 0OCQ reaches fair value

Put 0OCQ on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 20/100

Of which business quality 25 · Market factors (momentum, volatility) 27

Profitability 0
Margins and returns on capital today
Quality Growth 90
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 49
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−46.0%
Start year 2020 (pandemic). Over 10 years: −21.1% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,036.9% (2020) → −29,978.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 0OCQ, get fair value alerts →

Compare Transgene SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Integrated Oil & Gas” was too small, so the broader sector is used.)Energy · 991 stocks

Beats the sector median on 2/8 measures
Overall it trails its sector peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside +98.6% · Top 25%
Profitability
Return on assets −24.2% · Bottom 25%
Net margin (TTM) 0.0% · Below median
Growth and dividend
Revenue growth −12.2% · Bottom 25%
Balance sheet
Debt / equity 0.35× · Above median

Valuation Multiplesvs Energy median · lower = cheaper

P/B 0.45× · Cheapest 25%
P/S (TTM) 7.59× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Oil & gas

Similar stocks

10 more Integrated Oil & Gas stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Saudi Arabian Oil Company 2222 25.28 SAR 20.14 SAR −20%
Exxon Mobil Corporation XOM $162.75 $90.40 −44%
Chevron Corporation CVX $204.38 $92.05 −55%
PetroChina Company 601857 ¥11.21 ¥15.47 +38%
TotalEnergies SE TTE €74.51 €70.97 −5%
Reliance Industries Limited RELIANCE ₹1,168 ₹865.31 −26%
China Shenhua Energy Company 601088 ¥48.03 ¥31.96 −33%
ConocoPhillips explores for, COP $127.06 $91.42 −28%
CNOOC Limited 0883 HK$23.40 HK$39.91 +71%
Petróleo Brasileiro S.A PBR $20.37 $28.71 +41%

Explore undervalued stocks

More undervalued Energy stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Transgene SA · Fair Value
€1.62 +57%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Transgene SA Fair Value". https://www.fairvalue-calculator.com/stock/0OCQ

Frequently asked questions

Is Transgene SA (0OCQ) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €1.62 versus a price of €0.7000, about +131% upside (undervalued).
What is the fair value of 0OCQ?
Our model-based fair value for Transgene SA is €1.62 (as of Sep 24, 2026), built from audited fundamentals. The current price: €0.7000.
What is the quality score of 0OCQ?
Transgene SA has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Transgene SA (0OCQ)?
Our model-based price target is the fair value of €1.62 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario €1.07, optimistic scenario €2.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Transgene SA stock forecast for 2026?
Our models put fair value at €1.62, about +131% upside versus a price of €0.7000 (undervalued). Cautious scenario €1.07, optimistic scenario €2.02. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Transgene SA (0OCQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Transgene SA it is €1.62 per share (as of Sep 24, 2026), against a price of €0.7000. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Transgene SA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0OCQ trades below its calculated fair value: price €0.7000, fair value €1.62, a gap of about +131% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0OCQ?
No. The price is what the market pays today (€0.7000); the fair value is what the company's own numbers justify (€1.62). For Transgene SA the two are €0.9200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Transgene SA worth?
The market values Transgene SA at about €47.1M (market capitalisation, as of Sep 24, 2026). Per share that is €0.7000; our models calculate a fair value of €1.62 per share.
What do the bullish and bearish scenarios say about 0OCQ?
Our models span a range for Transgene SA: cautious scenario €1.07, base €1.62, optimistic €2.02 per share (as of Sep 24, 2026, price €0.7000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Transgene SA (0OCQ)?
Balance-sheet figures for Transgene SA (as of Sep 24, 2026): return on equity −54.8%, debt of 0.35 per unit of equity. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is 0OCQ from its 52-week high?
Transgene SA trades at €0.7000, about 53% below its 52-week high of €1.48 and at the low of €0.7000 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €1.62 is for.
Which stocks are comparable to Transgene SA?
From the same area (Energy) we also value Saudi Arabian Oil Company, Exxon Mobil Corporation, Chevron Corporation, PetroChina Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Transgene SA stock attractive at the current price?
The data as of Sep 24, 2026: price €0.7000, calculated fair value €1.62 (+131%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0OCQ calculated?
We run Transgene SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €1.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Transgene SA currently trades 57 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Transgene SA (0OCQ)?
The closing price on Oct 2, 2026 was €0.7000. Our model-based fair value is €1.62, about +131% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Transgene SA right now?
The large discount to fair value meets weak quality (20/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€1.07). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€1.07 to €2.02) leaves room in how you read the outcome.

Key figures of Transgene SA

How large is the market capitalisation of Transgene SA (0OCQ)?
The market capitalisation of Transgene SA is €47.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Transgene SA (0OCQ)?
The price-to-sales ratio of Transgene SA is 6.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Transgene SA (0OCQ)?
Earnings per share at Transgene SA are €−0.2140. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Transgene SA (0OCQ)?
The return on equity (ROE) of Transgene SA is −54.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Transgene SA (0OCQ)?
On an EBIT basis the return on assets of Transgene SA is −56.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Transgene SA (0OCQ)?
The operating margin of Transgene SA is −684% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Transgene SA (0OCQ)?
Revenue at Transgene SA is growing −12.2% versus a year earlier (3y avg −64.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Transgene SA (0OCQ) generate?
The free cash flow of Transgene SA is −€37.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Transgene SA (0OCQ) hold?
Transgene SA holds more cash than debt, €4.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Transgene SA in the live analysis

One click puts Transgene SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.